RAS野生型转移性结直肠癌维持治疗:帕尼单抗单药对比帕尼单抗联合氟尿嘧啶-亚叶酸
这项2期随机非劣效试验纳入229例RAS野生型不可切除转移性结直肠癌患者,诱导治疗后随机接受帕尼单抗联合氟尿嘧啶-亚叶酸(A组)或帕尼单抗单药(B组)维持治疗。
要点
- 帕尼单抗单药维持治疗的PFS劣于联合氟尿嘧啶-亚叶酸。
- 联合维持组3级及以上治疗相关不良事件发生率更高。
- RAS野生型mCRC抗EGFR维持治疗仍应考虑联合化疗。
核心结论
- 在RAS野生型转移性结直肠癌患者中,帕尼单抗单药维持治疗的PFS劣于帕尼单抗联合氟尿嘧啶-亚叶酸。
研究设计与样本
- 开放标签、随机2期非劣效试验,2015年7月7日至2017年10月27日在意大利多中心开展。
- 纳入229例RAS野生型不可切除转移性结直肠腺癌初治患者,1:1随机至A组(n=117)或B组(n=112)。
- 诱导治疗为帕尼单抗联合FOLFOX-4共8周期,随后A组接受帕尼单抗联合氟尿嘧啶-亚叶酸维持,B组接受帕尼单抗单药维持。
- 主要终点为10个月PFS,非劣效界值为B组对比A组风险比单侧90%CI上限1.515。
主要发现
- 中位随访18.0个月(IQR 13.1-23.3),共发生169例疾病进展或死亡事件。
- B组对比A组的HR单侧90%CI上限为1.857,超过非劣效界值1.515,B组劣于A组。
- 维持治疗期间,A组3级及以上治疗相关不良事件发生率高于B组(36例[42.4%] vs 16例[20.3%])。
- 维持治疗期间,A组帕尼单抗相关不良事件发生率高于B组(27例[31.8%] vs 13例[16.4%])。
临床怎么用
- RAS野生型mCRC患者经帕尼单抗联合FOLFOX-4诱导后,不推荐采用帕尼单抗单药作为维持治疗。
- 帕尼单抗联合氟尿嘧啶-亚叶酸维持治疗PFS更优,但需关注3级及以上治疗相关不良事件增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Few studies are available on the role of maintenance strategies after induction treatment regimens based on anti-epidermal growth factor receptors, and the optimal regimen for an anti-epidermal growth factor receptors-based maintenance treatment in patients with RAS wild-type metastatic colorectal cancer is still to be defined. OBJECTIVE: To determine whether maintenance therapy with single-agent panitumumab was noninferior to panitumumab plus fluorouracil and leucovorin after a 4-month induction treatment regimen. DESIGN, SETTING, AND PARTICIPANTS: This open-label, randomized phase 2 noninferiority trial was conducted from July 7, 2015, through October 27, 2017, at multiple Italian centers. Patients with RAS wild-type, unresectable metastatic colorectal adenocarcinoma who had not received previous treatment for metastatic disease were eligible. Induction therapy consisted of panitumumab plus FOLFOX-4 (panitumumab, 6 mg/kg, oxaliplatin, 85 mg/m2 at day 1, leucovorin calcium, 200 mg/m2, and fluorouracil, 400-mg/m2 bolus, followed by 600-mg/m2 continuous 24-hour infusion at days 1 and 2, every 2 weeks). Cutoff date for analyses was July 30, 2018. INTERVENTIONS: Patients were randomized (1:1) to first-line panitumumab plus FOLFOX-4 for 8 cycles followed by maintenance therapy with panitumumab plus fluorouracil-leucovorin (arm A) or panitumumab (arm B) until progressive disease, unacceptable toxic effects, or consent withdrawal. The minimization method was used to stratify randomization by previous adjuvant treatment and number of metastatic sites. MAIN OUTCOMES AND MEASURES: The prespecified primary end point was 10-month progression-free survival (PFS) analyzed on an intention-to-treat basis with a noninferiority margin of 1.515 for the upper limit of the 1-sided 90% CI of the hazard ratio (HR) of arm B vs A. RESULTS: Overall, 229 patients (153 male [66.8%]; median age, 64 years [interquartile range (IQR), 56-70 years]) were randomly assigned to arm A (n = 117) or arm B (n = 112). At a median follow-up of 18.0 months (IQR, 13.1-23.3 months]), a total of 169 disease progression or death events occurred. Arm B was inferior (upper limit of 1-sided 90% CI of the HR, 1.857). Ten-month PFS was 59.9% (95% CI, 51.5%-69.8%) in arm A vs 49.0% (95% CI, 40.5%-59.4%) in arm B (HR, 1.51; 95% CI, 1.11-2.07; P = .01). During maintenance, arm A had a higher incidence of grade 3 or greater treatment-related adverse events (36 [42.4%] vs 16 [20.3%]) and panitumumab-related adverse events (27 [31.8%] vs 13 [16.4%]), compared with arm B. CONCLUSIONS AND RELEVANCE: In patients with RAS wild-type metastatic colorectal cancer, maintenance therapy with single-agent panitumumab was inferior in terms of PFS compared with panitumumab plus fluorouracil-leucovorin, which slightly increased the treatment toxic effects. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02476045.
引用
- Pietrantonio F, Morano F, Corallo S, et al. Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019. PMID: 31268481. doi:10.1001/jamaoncol.2019.1467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。